{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:36:59Z","timestamp":1793824619265,"version":"4.6.1"},"reference-count":65,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2019,6,20]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>\n                    A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive phenotype characterised by decline in lung function, worsening quality of life and early mortality. Other than idiopathic pulmonary fibrosis (IPF), there are no approved drugs for fibrosing ILDs and a poor evidence base to support current treatments. Fibrosing ILDs with a progressive phenotype show commonalities in clinical behaviour and in the pathogenic mechanisms that drive disease worsening. Nintedanib is an intracellular inhibitor of tyrosine kinases that has been approved for treatment of IPF and has recently been shown to reduce the rate of lung function decline in patients with ILD associated with systemic sclerosis (SSc-ILD).\n                    <jats:italic>In vitro<\/jats:italic>\n                    data demonstrate that nintedanib inhibits several steps in the initiation and progression of lung fibrosis, including the release of pro-inflammatory and pro-fibrotic mediators, migration and differentiation of fibrocytes and fibroblasts, and deposition of extracellular matrix. Nintedanib also inhibits the proliferation of vascular cells. Studies in animal models with features of fibrosing ILDs such as IPF, SSc-ILD, rheumatoid arthritis-ILD, hypersensitivity pneumonitis and silicosis demonstrate that nintedanib has anti-fibrotic activity irrespective of the trigger for the lung pathology. This suggests that nintedanib inhibits fundamental processes in the pathogenesis of fibrosis. A trial of nintedanib in patients with progressive fibrosing ILDs other than IPF (INBUILD) will report results in 2019.\n                  <\/jats:p>","DOI":"10.1183\/13993003.00161-2019","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:25:21Z","timestamp":1562631921000},"page":"1900161","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":256,"title":["Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases"],"prefix":"10.1183","volume":"54","author":[{"given":"Lutz","family":"Wollin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg H.W.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth F.","family":"Redente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.H.","family":"Riches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Stowasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozsa","family":"Schlenker-Herceg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-1467","authenticated-orcid":false,"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"2024102101023962000_54.3.1900161.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2024102101023962000_54.3.1900161.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2024102101023962000_54.3.1900161.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018"},{"key":"2024102101023962000_54.3.1900161.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200403-331OC"},{"key":"2024102101023962000_54.3.1900161.5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease","volume":"69","author":"Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024102101023962000_54.3.1900161.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes289"},{"key":"2024102101023962000_54.3.1900161.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2685"},{"key":"2024102101023962000_54.3.1900161.8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"key":"2024102101023962000_54.3.1900161.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60235-9"},{"key":"2024102101023962000_54.3.1900161.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00131912"},{"key":"2024102101023962000_54.3.1900161.11","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0100-2018"},{"key":"2024102101023962000_54.3.1900161.12","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s12325-019-00992-9","article-title":"Management of fibrosing interstitial lung diseases","volume":"36","author":"Maher","year":"2019","journal-title":"Adv Ther"},{"key":"2024102101023962000_54.3.1900161.13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0510"},{"key":"2024102101023962000_54.3.1900161.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00069307"},{"key":"2024102101023962000_54.3.1900161.15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/BOR.0000000000000112","article-title":"Endothelial dysfunction in systemic sclerosis","volume":"26","author":"Altorok","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"2024102101023962000_54.3.1900161.16","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00003214"},{"key":"2024102101023962000_54.3.1900161.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2008.02.012"},{"key":"2024102101023962000_54.3.1900161.18","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200601-004TK"},{"key":"2024102101023962000_54.3.1900161.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201212-2297OC"},{"key":"2024102101023962000_54.3.1900161.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61144-1"},{"key":"2024102101023962000_54.3.1900161.21","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0050OC"},{"key":"2024102101023962000_54.3.1900161.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0694"},{"key":"2024102101023962000_54.3.1900161.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9962-7"},{"key":"2024102101023962000_54.3.1900161.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6307"},{"key":"2024102101023962000_54.3.1900161.25","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.244129"},{"key":"2024102101023962000_54.3.1900161.26","first-page":"S4","article-title":"The central role of T cells in rheumatoid arthritis","volume":"25","author":"Cope","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2024102101023962000_54.3.1900161.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes090"},{"key":"2024102101023962000_54.3.1900161.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.9.3277"},{"key":"2024102101023962000_54.3.1900161.29","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90428-F"},{"key":"2024102101023962000_54.3.1900161.30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1163"},{"key":"2024102101023962000_54.3.1900161.31","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90334-4"},{"key":"2024102101023962000_54.3.1900161.32","first-page":"PA903","article-title":"Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease","volume":"50","author":"Wollin","year":"2017","journal-title":"Eur Respir J"},{"key":"2024102101023962000_54.3.1900161.33","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200808-1201OC"},{"key":"2024102101023962000_54.3.1900161.34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116775"},{"key":"2024102101023962000_54.3.1900161.35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","article-title":"High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis","volume":"150","author":"Hoffmann-Vold","year":"2016","journal-title":"Chest"},{"key":"2024102101023962000_54.3.1900161.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066084"},{"key":"2024102101023962000_54.3.1900161.37","first-page":"A2397","article-title":"Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor","volume":"195","author":"Tandon","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101023962000_54.3.1900161.38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.intimp.2019.03.061","article-title":"Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib","volume":"72","author":"Bellamri","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2024102101023962000_54.3.1900161.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210823"},{"key":"2024102101023962000_54.3.1900161.40","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00007713"},{"key":"2024102101023962000_54.3.1900161.41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12931-017-0654-2","article-title":"Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity","volume":"18","author":"Sato","year":"2017","journal-title":"Respir Res"},{"key":"2024102101023962000_54.3.1900161.42","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-014-0157-3"},{"key":"2024102101023962000_54.3.1900161.43","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00174914"},{"key":"2024102101023962000_54.3.1900161.44","first-page":"A4940","article-title":"The effect of nintedanib compared to pirfenidone on serum-stimulated proliferation of human primary lung fibroblasts at clinically relevant concentrations","volume":"191","author":"Schuett","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101023962000_54.3.1900161.45","first-page":"A2008","article-title":"Nintedanib attenuates motility of lung fibroblasts from patients with idiopathic pulmonary fibrosis","volume":"189","author":"Wollin","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101023962000_54.3.1900161.46","first-page":"A2384","article-title":"The effect of nintedanib on platelet derived growth factor-stimulated contraction of human primary lung fibroblasts","volume":"193","author":"Wollin","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101023962000_54.3.1900161.47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207109"},{"key":"2024102101023962000_54.3.1900161.48","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.208223"},{"key":"2024102101023962000_54.3.1900161.49","doi-asserted-by":"crossref","first-page":"e96352","DOI":"10.1172\/jci.insight.96352","article-title":"Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung","volume":"2","author":"Sava","year":"2017","journal-title":"JCI Insight"},{"key":"2024102101023962000_54.3.1900161.50","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200308-1111OC"},{"key":"2024102101023962000_54.3.1900161.51","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2403006"},{"key":"2024102101023962000_54.3.1900161.52","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/cvr\/cvy186","article-title":"Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodeling unaltered in experimental pulmonary hypertension","volume":"115","author":"Rol","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2024102101023962000_54.3.1900161.53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10456-017-9543-z","article-title":"Effects of nintedanib on the microvascular architecture in a lung fibrosis model","volume":"20","author":"Ackermann","year":"2017","journal-title":"Angiogenesis"},{"key":"2024102101023962000_54.3.1900161.54","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/01902148.2017.1339141","article-title":"Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model","volume":"43","author":"Lee","year":"2017","journal-title":"Exp Lung Res"},{"key":"2024102101023962000_54.3.1900161.55","doi-asserted-by":"crossref","first-page":"L998","DOI":"10.1152\/ajplung.00304.2017","article-title":"Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease","volume":"314","author":"Redente","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2024102101023962000_54.3.1900161.56","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.radonc.2017.07.014","article-title":"Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: a preclinical study with a high precision image-guided irradiator","volume":"124","author":"De Ruysscher","year":"2017","journal-title":"Radiother Oncol"},{"key":"2024102101023962000_54.3.1900161.57","doi-asserted-by":"crossref","first-page":"E1974","DOI":"10.3390\/molecules23081974","article-title":"Protective effects of nintedanib against polyhexamethylene guanidine phosphate-induced lung fibrosis in mice","volume":"23","author":"Kim","year":"2018","journal-title":"Molecules"},{"key":"2024102101023962000_54.3.1900161.58","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1042\/CS20170134","article-title":"Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease","volume":"131","author":"Liu","year":"2017","journal-title":"Clin Sci"},{"key":"2024102101023962000_54.3.1900161.59","doi-asserted-by":"publisher","DOI":"10.1038\/srep44545"},{"key":"2024102101023962000_54.3.1900161.60","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41419-018-0792-6","article-title":"Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy","volume":"9","author":"Pi\u00f1ol-Jurado","year":"2018","journal-title":"Cell Death Dis"},{"key":"2024102101023962000_54.3.1900161.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690"},{"key":"2024102101023962000_54.3.1900161.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102101023962000_54.3.1900161.63","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2024102101023962000_54.3.1900161.64","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000212"},{"key":"2024102101023962000_54.3.1900161.65","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01565-2015"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00161-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:39:50Z","timestamp":1740364790000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00161-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":65,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9,19]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1183\/13993003.00161-2019"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00161-2019","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]}}}